MedPath

Prospective study of Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration in Japanese Patients

Phase 4
Conditions
Exudative Age-Related Macular Degeneration
Registration Number
JPRN-UMIN000027799
Lead Sponsor
Akita University Department of Ophthalmology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1) previous treatment for AMD 2) polypoidal choroidal vasculopathy 3) retinal angiomatous proliferation 4) diabetic maculopathy, retinal vascular occlusion, or idiopathic macular telangiectasia

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The mean changes of best-corrected visual acuity at month 24 compared with baseline
Secondary Outcome Measures
NameTimeMethod
The prevalence of eyes with only ranibizumab by PRN (pro re nata)
© Copyright 2025. All Rights Reserved by MedPath